DOP90: Amphiregulin promotes colitis-associated intestinal fibrosis through activation of PI3K/AKT signaling in Intestinal fibroblastsECCO'24 Stockholm 2024
OP01: PROFILE: a multi-centre, randomised, open-label, biomarker-stratified clinical trial of treatment strategies for patients with newly-diagnosed Crohn’s diseaseECCO'24 Stockholm 2024
OP02: IL23R-CAR-Tregs: creating a therapeutic breakthrough for Crohn’s DiseaseECCO'24 Stockholm 2024
OP04: Endoscopic healing in paediatric IBD perpetuates a persistent signature characterized by pathogenic Th17 cells and tissue-associated molecular and microbial drivers of diseaseECCO'24 Stockholm 2024
OP05: Primary efficacy and safety of mirikizumab in moderate to severe Crohn’s Disease: results of the treat-through VIVID 1 studyECCO'24 Stockholm 2024
OP06: Risankizumab Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomised Phase 3 COMMAND StudyECCO'24 Stockholm 2024
OP07: Consistent IBD treatment approaches across South Asian and White ethnicities despite phenotypic variations: a study of 33,157 patients using the IBD BioResourceECCO'24 Stockholm 2024
OP08: Multi-ancestry genome-wide association study of inflammatory bowel disease identifies 125 novel loci and directly implicates new genes in disease susceptibilityECCO'24 Stockholm 2024
OP09: Oral ritlecitinib and brepocitinib in patients with moderate to severe active Crohn’s Disease: Data from the PIZZICATO umbrella studyECCO'24 Stockholm 2024
OP10: Efficacy and safety of upadacitinib in patients with moderately to severely active Crohn’s Disease: results from the U-ENDURE long-term extensionECCO'24 Stockholm 2024
OP11: Exploring the potential clinical utility of NUDT15 pharmacogenetic testing in clinical practice: a ‘focused reverse phenotyping’ study in the UK IBD BioresourceECCO'24 Stockholm 2024
OP12: Mirikizumab improves fatigue, bowel urgency, and quality of life in patients with moderately to severely active Crohn’s Disease: Results from a phase 3 clinical trialECCO'24 Stockholm 2024
OP13: Anti-integrin ⍺vβ6 autoantibodies are increased in PSC-IBD and correlate with liver disease severityECCO'24 Stockholm 2024
OP14: Effect of mirikizumab on clinical and endoscopic outcomes after 1 anti-TNF failure in patients with moderately to severely active Ulcerative ColitisECCO'24 Stockholm 2024
OP15: High-definition white light endoscopy with segmental re-inspection is non-inferior compared to dye-based chromoendoscopy in Inflammatory Bowel Disease: the randomized controlled HELIOS trialECCO'24 Stockholm 2024
OP17: IBD ulcers are characterized by bioactive interleukin-1 and transcriptomic hallmarks of stromal cell state reprogrammingECCO'24 Stockholm 2024